Does the use of insulin faster aspart vs. aspart lead to the prolonged glycemic time in range in children with type 1 diabetes who use continuous glucose monitoring?

被引：0
|
作者：
Kowalczyk-Korcz, E. [1 ]
Dyminska, M. [1 ]
Szypowska, A. [1 ]
机构：
[1] Med Univ Warsaw, Dept Pediat Diabetol & Pediat, Warsaw, Poland
来源：
HORMONE RESEARCH IN PAEDIATRICS | 2024年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-75
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [21] Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial
    Heise, Tim
    Zijlstra, Eric
    Nosek, Leszek
    Rikte, Tord
    Haahr, Hanne
    DIABETES OBESITY & METABOLISM, 2017, 19 (02): : 208 - 215
  • [22] Biphasic insulin aspart vs. human insulin in adolescents with type 1 diabetes on multiple daily insulin injections
    Mortensen, H
    Kocova, M
    Teng, LY
    Keiding, J
    Bruckner, I
    Philotheou, A
    PEDIATRIC DIABETES, 2006, 7 (01) : 4 - 10
  • [23] Earlier Onset and Higher Early Exposure of Faster-Acting Insulin Aspart vs. Insulin Aspart in Adults Is Retained in Children and Adolescents with T1D
    Danne, Thomas
    Biester, Torben
    Fath, Maryam
    Thorsson, Lars
    Rikte, Tord
    Kordonouri, Olga
    Haahr, Hanne
    DIABETES, 2015, 64 : A247 - A247
  • [24] Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus
    Tim Heise
    Kirstine Stender-Petersen
    Ulrike Hövelmann
    Jacob Bonde Jacobsen
    Leszek Nosek
    Eric Zijlstra
    Hanne Haahr
    Clinical Pharmacokinetics, 2017, 56 : 649 - 660
  • [25] Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus
    Heise, Tim
    Stender-Petersen, Kirstine
    Hoevelmann, Ulrike
    Jacobsen, Jacob Bonde
    Nosek, Leszek
    Zijlstra, Eric
    Haahr, Hanne
    CLINICAL PHARMACOKINETICS, 2017, 56 (06) : 649 - 660
  • [26] Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Subjects with Type 1 Diabetes Using CSII
    Bode, Bruce
    Hyveled, Liselotte
    Tamer, Soren Can
    Ybanez, Patria
    Demissie, Marek
    DIABETES, 2015, 64 : A253 - A253
  • [27] Insulin aspart - A review of its use in the management of type 1 or 2 diabetes mellitus
    Reynolds, NA
    Wagstaff, AJ
    DRUGS, 2004, 64 (17) : 1957 - 1974
  • [28] Insulin aspart - A review of its use in the management of type 1 and 2 diabetes mellitus
    Chapman, TM
    Noble, S
    Goa, KL
    DRUGS, 2002, 62 (13) : 1945 - 1981
  • [29] Double-Blind Mealtime Faster-Acting Insulin Aspart vs. Insulin Aspart in Basal-Bolus Improves Glycemic Control in T1D: The Onset® 1 Trial
    Russell-Jones, David
    Bode, Bruce W.
    De Block, Christophe
    Franek, Edward
    Heller, Simon R.
    Mathieu, Chantal
    Philis-Tsimikas, Athena
    Rose, Ludger
    Woo, Vincent C.
    Osterskov, Anne Birk
    Graungaard, Tina
    Bergenstal, Richard
    DIABETES, 2016, 65 : A77 - A77
  • [30] HIGHER EARLY EXPOSURE AND GREATER EARLY GLUCOSE-LOWERING EFFECT WITH FASTER-ACTING INSULIN ASPART VS INSULIN ASPART IN ELDERLY AND YOUNGER ADULTS WITH TYPE 1 DIABETES (T1D)
    Hoevelmann, U.
    Zijlstra, E.
    Stender-Petersen, K.
    Jacobsen, J. B.
    Heise, T.
    Haahr, H.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A44 - A45
12345